DURECT Corporation Surges 265% Amid Acquisition Proposal and FDA Breakthrough Designation

DURECT Corporation Overview

DURECT Corporation (Nasdaq: DRRX) is a late-stage biopharmaceutical company founded in 1998 and headquartered in Cupertino, California. The firm specializes in epigenetic therapies that target dysregulated DNA methylation to address conditions such as acute organ injury and cancer. Its lead clinical candidate, larsucosterol (DUR-928), is under development for alcohol-associated hepatitis (AH). Additionally, DURECT’s SABER® platform delivers POSIMIR® (bupivacaine solution) for post-surgical pain; POSIMIR is FDA-approved and exclusively licensed to Innocoll Pharmaceuticals for commercialization in the United States.

Corporate Structure and Experience

DURECT employs between 51 and 200 professionals across research, clinical development, regulatory affairs, and corporate functions. Its executive team is led by President and CEO James E. Brown, D.V.M., with Chief Medical Officer Norman Sussman, M.D., overseeing clinical strategy. The company’s research infrastructure supports multi-site trials spanning the U.S., Europe, the U.K., and Australia, reflecting over two decades of experience in drug formulation and delivery technologies.

Epigenetic therapies by Sangharsh Lohakare

Recent Developments and News

On May 21, 2024, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to larsucosterol for the treatment of patients with severe AH. This designation followed topline results announced in November 2023 from the Phase 2b AHFIRM trial, which enrolled 307 patients across over 60 sites. DURECT expects to finalize the design of its registrational Phase 3 trial in the second half of 2025, with topline data anticipated within two years of the May 13, 2025 announcement.

Web and investor materials highlight epigenetic modulation’s potential role in addressing AH’s 90-day mortality rate, which is reported to be approximately 30%. Separately, POSIMIR continues to be marketed by Innocoll as a non-opioid analgesic for infiltration use.

On July 28, 2025, Bausch Health Americas, Inc. proposed to acquire DURECT via tender offer. DURECT filed its initial SC 14D9C communication on July 29, 2025, outlining risks related to timing, stockholder participation, regulatory approvals, and integration. The tender offer process has not yet commenced.

Financial and Strategic Analysis

As of July 29, 2025, DRRX stock closed at $2.0198, an increase of 265.44% with a volume of 5,568,601 shares traded on the NASDAQ. The change in share price reflects market reactions to the acquisition proposal and anticipated developments regarding the Phase 3 trial. Key strategic drivers include:

• Breakthrough Therapy designation, which allows for rolling reviews and intensive guidance from the FDA.
• Planned registrational Phase 3 study, which could enhance the likelihood of approval for larsucosterol.
• Licensing revenues from POSIMIR, providing an additional cash flow stream.
• The proposed acquisition by Bausch Health Americas, which may facilitate operational efficiencies but introduces integration and regulatory risks.

SEC filings caution stakeholders that completion of the tender offer and merger depends on customary closing conditions, including sufficient share tendering and regulatory approvals. DURECT management emphasizes ongoing communication with stakeholders as the process evolves.

Market Position and Industry Context

Alcohol-associated hepatitis accounts for approximately 164,000 annual hospitalizations in the U.S., with no FDA-approved therapeutic options and a reported 90-day mortality rate near 30%. The current standard of care primarily uses corticosteroids, which have demonstrated inconsistent survival benefits and have associated contraindications. Liver transplantation, while effective in some cases, is limited by organ availability and high costs.

DURECT’s epigenetic approach is currently one of few mechanisms in clinical development targeting AH. Beyond AH, the company is investigating other conditions related to epigenomic dysregulation, including acute organ injuries and cancer. POSIMIR’s presence in the analgesics market further solidifies DURECT's position in the drug delivery sector.

tl;dr

DURECT shares rose 265.44% to $2.0198 on July 29, 2025, following a proposal from Bausch Health Americas to acquire the company. The FDA granted Breakthrough Therapy designation for larsucosterol on May 21, 2024, and DURECT announced plans for a registrational Phase 3 trial on May 13, 2025. The tender offer process has not started; SEC filings on July 29, 2025, detail timing, participation, and regulatory risks. Phase 2b AHFIRM data indicated up to a 58% reduction in 90-day mortality among U.S. patients, supporting the next phase of development. With no approved treatments for AH, larsucosterol’s progress and the proposed acquisition may influence DURECT’s outlook through 2027.